Cyclacillin
Cyclapen-w (cyclacillin) is a small molecule pharmaceutical. Cyclacillin was first approved as Cyclapen-w on 1982-01-01. It is used to treat haemophilus infections, pneumococcal infections, respiratory tract infections, staphylococcal infections, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
respiratory tract diseases | D012140 |
urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
haemophilus infections | EFO_1001127 | D006192 | — |
pneumococcal infections | EFO_0000772 | D011008 | J13 |
respiratory tract infections | — | D012141 | J06.9 |
staphylococcal infections | — | D013203 | A49.01 |
urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
195 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vitamin b 12 deficiency | D014806 | EFO_0000734 | E53.8 | 2 | 2 | 2 | 3 | 15 | 22 |
Anemia | D000740 | EFO_0004272 | D64.9 | — | 3 | 2 | 4 | 5 | 12 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 1 | 2 | — | 5 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | 1 | 2 | 5 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 2 | 1 | — | 4 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | 2 | 1 | 4 |
Neoplasms | D009369 | C80 | — | — | 1 | 2 | — | 3 | |
Vasoplegia | D056987 | — | 2 | — | 1 | — | 3 | ||
Cognitive dysfunction | D060825 | G31.84 | 1 | — | — | 1 | 1 | 3 | |
Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | — | — | 1 | 2 | 3 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | 1 | 8 | 5 | — | 1 | 13 | ||
Coronary artery disease | D003324 | I25.1 | — | 2 | 1 | — | 1 | 4 | |
T-cell lymphoma peripheral | D016411 | C84.9 | 2 | 3 | 1 | — | — | 4 | |
Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 2 | 2 | — | 2 | 4 |
Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | 1 | 3 | |
Lung neoplasms | D008175 | C34.90 | — | 3 | 1 | — | — | 3 | |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 1 | — | 2 | 3 |
Urinary bladder neoplasms | D001749 | C67 | — | 1 | 1 | — | — | 2 | |
Transitional cell carcinoma | D002295 | — | 1 | 1 | — | — | 2 | ||
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | 1 | 2 |
Show 19 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | — | — | 4 | 5 | |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | 1 | 4 |
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | 1 | 2 |
Head and neck neoplasms | D006258 | — | 2 | — | — | — | 2 | ||
Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 2 | — | — | — | 2 |
Nasopharyngeal neoplasms | D009303 | — | 2 | — | — | — | 2 | ||
B-cell lymphoma | D016393 | 1 | 2 | — | — | — | 2 | ||
Coronary disease | D003327 | — | 1 | — | — | — | 1 | ||
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | — | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | 1 | — | — | — | 2 | 3 |
T-cell lymphoma cutaneous | D016410 | C84.A | 2 | — | — | — | — | 2 | |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
Pancreatic ductal carcinoma | D021441 | 1 | — | — | — | — | 1 | ||
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 | ||
Adenocarcinoma | D000230 | 1 | — | — | — | — | 1 | ||
Sezary syndrome | D012751 | C84.1 | 1 | — | — | — | — | 1 | |
Primary cutaneous anaplastic large cell lymphoma | D054446 | C86.6 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | — | — | 3 | 3 | ||
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
Hyperhomocysteinemia | D020138 | — | — | — | — | 2 | 2 | ||
Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | — | — | 2 | 2 |
Aphthous stomatitis | D013281 | EFO_0003938 | K12.0 | — | — | — | — | 2 | 2 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
Diabetes complications | D048909 | — | — | — | — | 1 | 1 | ||
Diabetic foot | D017719 | EFO_1001459 | — | — | — | — | 1 | 1 | |
Delirium | D003693 | R41.0 | — | — | — | — | 1 | 1 | |
Neutropenia | D009503 | D70 | — | — | — | — | 1 | 1 |
Show 32 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CYCLACILLIN |
INN | ciclacillin |
Description | Cyclacillin is a penicillin. It has a role as an antibacterial drug. |
Classification | Small molecule |
Drug class | penicillins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(=O)O |
Identifiers
PDB | — |
CAS-ID | 3485-14-1 |
RxCUI | 2968 |
ChEMBL ID | CHEMBL1200356 |
ChEBI ID | 31444 |
PubChem CID | 19003 |
DrugBank | DB01000 |
UNII ID | 72ZJ154X86 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
3,354 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more